By Nicholas G. Miller
Eli Lilly is scheduled to report its fourth-quarter results before the market opens Wednesday. Here is what you need to know.
PROFIT: Analysts polled by FactSet expect the company to post net income of $5.89 billion, up from $4.41 billion the year before.
ADJUSTED EARNINGS: Stripping out one-time items, earnings are expected to come in at $6.91 a share, compared with $5.32 a share in the year-ago quarter.
SALES: Wall Street is forecasting $17.94 billion in sales, up from $13.53 billion the year before.
WHAT TO WATCH:
--Eli Lilly has seen soaring demand for its GLP-1 weight-loss drugs Zepbound and Mounjaro but is now seeking to remove obstacles and expand access to grow the drugs' market even further. Investors will be listening for commentary about sales through the company's direct-to-consumer platform and the impact of price cuts on demand.
--Eli Lilly is also preparing to launch a new weight-loss pill called orforglipron. Analysts have said the convenience of the pill could spark even more demand than Zepbound and Mounjaro, which are injected weekly, as some patients are averse to injections. Investors will be listening for discussion of the drug's launch once it gets FDA approval.
--Last month, the company agreed to acquire Ventyx Biosciences, which makes pills that can treat inflammatory diseases, for more than $1 billion. Investors will be eager to hear about the benefits the acquisition will provide and what the company's acquisition approach will be for the rest of the year.
Write to Nicholas G. Miller at nicholas.miller@wsj.com.
(END) Dow Jones Newswires
February 03, 2026 12:37 ET (17:37 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.